Longeveron (LGVN) Depreciation & Amortization (CF) (2023 - 2026)
Longeveron (LGVN) posted quarterly Depreciation & Amortization (CF) of $252000.0 for Q1 2026, down 40.14% year-over-year from $421000.0 in Q1 2025, and down 9.35% quarter-over-quarter from $278000.0 in Q4 2025.
Longeveron (LGVN) Depreciation & Amortization (CF) (2023 - 2026) Analysis & Trends
Longeveron's Depreciation & Amortization (CF) history runs 4 years deep, the most recent figure standing at $252000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 40.14% year-over-year to $252000.0; the TTM figure through Mar 2026 stood at $1.1 million (down 6.21% YoY), while the FY2025 annual figure was $1.2 million, up 27.97% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $252000.0, down from $278000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $421000.0 in Q1 2025, with the low at $229000.0 in Q2 2024.
- The 4-year median for Depreciation & Amortization (CF) is $242000.0 (2024), against an average of $260153.8.
- The sharpest annual moves came in 2025 and 2026: Depreciation & Amortization (CF) soared 67.06% in 2025, then slumped 40.14% in 2026.
- Longeveron's Depreciation & Amortization (CF) stood at $236000.0 in 2023, then climbed by 2.54% to $242000.0 in 2024, then grew by 14.88% to $278000.0 in 2025, then dropped by 9.35% to $252000.0 in 2026.
- Business Quant data shows LGVN's Depreciation & Amortization (CF) at $252000.0 in Q1 2026, $278000.0 in Q4 2025, and $264000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Longeveron | 26.51 Mn | 16.41 Mn | 182,000.00 | 221,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 221,000.00 |
| Jun 30, 2026 | 221,000.00 |
| Mar 31, 2026 | 252,000.00 |
| Mar 31, 2026 | 252,000.00 |
| Dec 31, 2025 | 278,000.00 |
| Dec 31, 2025 | 278,000.00 |
| Sep 30, 2025 | 264,000.00 |
| Sep 30, 2025 | 264,000.00 |
| Jun 30, 2025 | 263,000.00 |
| Jun 30, 2025 | 263,000.00 |
| Mar 31, 2025 | 421,000.00 |
| Mar 31, 2025 | 421,000.00 |
| Dec 31, 2024 | 242,000.00 |
| Dec 31, 2024 | 242,000.00 |
| Sep 30, 2024 | 235,000.00 |
| Sep 30, 2024 | 235,000.00 |
| Jun 30, 2024 | 229,000.00 |
| Jun 30, 2024 | 229,000.00 |
| Mar 31, 2024 | 252,000.00 |
| Mar 31, 2024 | 252,000.00 |